These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32996106)

  • 21. Human pharmaceuticals in surface waters. Implementation of a prioritization methodology and application to the French situation.
    Besse JP; Garric J
    Toxicol Lett; 2008 Jan; 176(2):104-23. PubMed ID: 18077113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Environmental assessment of Norwegian priority pharmaceuticals based on the EMEA guideline.
    Grung M; Källqvist T; Sakshaug S; Skurtveit S; Thomas KV
    Ecotoxicol Environ Saf; 2008 Oct; 71(2):328-40. PubMed ID: 18068226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Environmental risk assessment of medicinal products for human use according to European Commission recommendations.
    Huschek G; Hansen PD; Maurer HH; Krengel D; Kayser A;
    Environ Toxicol; 2004 Jun; 19(3):226-40. PubMed ID: 15101038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins.
    Althunian TA; de Boer A; Mantel-Teeuwisse AK; Groenwold RHH; Gispen-de Wied CC; Leufkens HGM; Klungel OH
    Clin Ther; 2020 Aug; 42(8):1588-1594. PubMed ID: 32782135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
    Carr M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A; Montané J
    Crit Rev Toxicol; 2019 Aug; 49(7):580-596. PubMed ID: 31846383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Biosimilars": towards fewer obstacles to their use.
    Prescrire Int; 2015 Mar; 24(158):80-1, 83. PubMed ID: 25897464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspective.
    Refalo N; Chetcuti D; Tanti A; Serracino-Inglott A; Borg JJ
    Saudi Pharm J; 2017 Feb; 25(2):280-289. PubMed ID: 28344480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Environmental risk assessment for medicinal products containing genetically modified organisms.
    Anliker B; Longhurst S; Buchholz CJ
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):52-7. PubMed ID: 19940966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges of safety evaluation.
    Wiesner J
    J Ethnopharmacol; 2014 Dec; 158 Pt B():467-70. PubMed ID: 25150528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [How does a new medicine reach the patient?].
    Visser BJ; Korevaar DA; Mokhles MM; Vermeer-Pragt W; de Boer A; Giezen TJ
    Ned Tijdschr Geneeskd; 2020 Jul; 164():. PubMed ID: 32779914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and evaluation of computer models for predicting environmental concentrations of pharmaceuticals and veterinary products in the Nordic environment.
    Wajsman D; Rudén C
    J Expo Sci Environ Epidemiol; 2006 Jan; 16(1):85-97. PubMed ID: 16030525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sources, pathways, and relative risks of contaminants in surface water and groundwater: a perspective prepared for the Walkerton inquiry.
    Ritter L; Solomon K; Sibley P; Hall K; Keen P; Mattu G; Linton B
    J Toxicol Environ Health A; 2002 Jan; 65(1):1-142. PubMed ID: 11809004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.